Overview

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Status:
Not yet recruiting
Trial end date:
2026-11-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
Bristol Myers Squibb Company (BMS)